Equities

Ibio Inc

Ibio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.36
  • Today's Change2.21 / 192.17%
  • Shares traded117.36k
  • 1 Year change-93.09%
  • Beta-3.6117
Data delayed at least 15 minutes, as of Mar 27 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

  • Revenue in USD (TTM)50.00k
  • Net income in USD-20.77m
  • Incorporated2008
  • Employees26.00
  • Location
    Ibio Inc8800 HSC PkwyBRYAN 77807United StatesUSA
  • Phone+1 (979) 446-0027
  • Fax+1 (302) 636-5454
  • Websitehttps://www.ibioinc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hepion Pharmaceuticals Inc0.00-47.82m10.84m25.00--0.6634-----12.51-12.510.004.210.00----0.00-94.36-51.33-110.58-57.30-----------4,805.570.00-------38.55------
Chemomab Therapeutics Ltd - ADR0.00-24.22m10.94m37.00--0.6436-----2.12-2.120.001.200.00-------74.28---90.33----------------------12.39------
Monopar Therapeutics Inc0.00-9.48m10.96m11.00--1.58-----0.713-0.7130.000.46560.00----0.00-82.34-47.93-99.10-52.12------------0.00-------15.52------
Pioneer Green Farms Inc9.30k-520.65k11.02m6.00------1,185.43-0.0216-0.02160.0004-0.02720.01470.7101--1,550.00-82.36------41.40---5,598.39--0.0131-10.8924.35---100.00---86.80------
Endexx Corp4.64m6.93m11.47m--1.71--1.932.480.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
Guardion Health Sciences Inc12.04m-10.11m11.49m12.00--1.49--0.9544-8.20-8.209.556.040.58583.216.621,003,258.00-44.63-103.85-48.35-113.3441.3742.22-76.19-303.777.26--0.00--52.7790.7735.89---31.63--
Ibio Inc50.00k-20.77m11.71m26.00--1.19--234.14-21.91-27.300.04372.840.0012--0.01291,923.08-48.41-28.09-113.84-32.63-----41,546.00-1,467.30---518.330.5942---100.00--0.9764--42.90--
ELEVAI Labs Inc1.15m-3.80m11.96m16.00------10.37-0.2191-0.21910.0665-0.0095----------------66.47---329.28--0.4729-7.67----92,222.89---129.41------
Inhibitor Therapeutics Inc0.0010.46m12.04m3.002.761.87----0.02540.02540.000.03750.00----0.00217.1839.86249.2559.57------------0.000.00----2,489.99------
Eterna Therapeutics Inc68.00k-21.68m12.12m8.00--5.43--178.22-4.08-4.080.01280.41280.0019--0.09888,500.00-60.69-169.05-75.78-223.00-173.53---31,864.71-682.61---33.190.7813-----68.8911.84---58.86--
Akari Therapeutics PLC (ADR)0.00-17.75m12.28m15.00--3.87-----5.68-5.680.000.48110.00----0.00-139.31-144.04-483.25-325.18-----------15.770.00-------1.86------
Moleculin Biotech Inc0.00-26.27m12.34m15.00--0.3134-----13.52-13.520.0017.680.00----0.00-50.09-44.48-55.51-48.83------------0.00-------82.62--19.06--
BioNexus Gene Lab Corp10.34m-3.09m12.37m9.00--1.29--1.20-0.1801-0.18010.67540.54451.078.115.701,148,592.00-32.124.60-37.996.2913.5614.80-29.923.524.36-204.890.000.00-18.21151.93-147.36---29.67--
Janone Inc39.61m155.00k12.50m199.0025.340.862510.510.31570.09954.0711.155.851.24--12.55199,050.300.4838-17.150.8217-40.7319.2323.820.3913-13.91----0.00---1.03-0.9484208.305.2046.85--
Paranovus Entertainment Technology Ltd51.46m-42.62m12.62m80.00--1.18--0.2452-7.16-7.499.891.461.1859.614.15643,209.90-91.12-23.19-119.36-27.214.9223.09-77.15-24.253.97-2,465.220.00--9.689.80-45.84---21.93--
Intelligent Bio Solutions Inc2.46m-13.40m12.66m17.00--0.1669--5.14-131.37-131.3720.9126.670.18312.419.09144,726.50-99.96-80.65-157.15-224.8420.90---545.95-948.540.3864--0.1602--187.51367.97-28.00------
Data as of Mar 27 2024. Currency figures normalised to Ibio Inc's reporting currency: US Dollar USD

Institutional shareholders

7.22%Per cent of shares held by top holders
HolderShares% Held
Sabby Management LLCas of 31 Dec 2023176.75k5.07%
Citadel Securities LLCas of 31 Dec 202325.39k0.73%
Warberg Asset Management LLCas of 31 Dec 202319.00k0.55%
UBS Securities LLCas of 31 Dec 202318.00k0.52%
BlackRock Fund Advisorsas of 31 Dec 20236.89k0.20%
Tower Research Capital LLCas of 31 Dec 20234.78k0.14%
Pennsylvania State Employees' Retirement Systemas of 31 Dec 2021411.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023231.000.01%
Morgan Stanley & Co. LLCas of 31 Dec 2023108.000.00%
RBC Dominion Securities, Inc.as of 31 Dec 202370.000.00%
More ▼
Data from 31 Dec 2021 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.